258 related articles for article (PubMed ID: 29082547)
1.
Li W; Lao-Kaim NP; Roussakis AA; Martín-Bastida A; Valle-Guzman N; Paul G; Loane C; Widner H; Politis M; Foltynie T; Barker RA; Piccini P
Mov Disord; 2018 Jan; 33(1):117-127. PubMed ID: 29082547
[TBL] [Abstract][Full Text] [Related]
2. Reproducibility of PET measurement for presynaptic dopaminergic functions using L-[β-(11)C]DOPA and [(18)F]FE-PE2I in humans.
Suzuki M; Ito H; Kodaka F; Takano H; Kimura Y; Fujiwara H; Sasaki T; Takahata K; Nogami T; Nagashima T; Nengaki N; Kawamura K; Zhang MR; Varrone A; Halldin C; Okubo Y; Suhara T
Nucl Med Commun; 2014 Mar; 35(3):231-7. PubMed ID: 24468851
[TBL] [Abstract][Full Text] [Related]
3. PET imaging of dopamine transporters with [(18)F]FE-PE2I: Effects of anti-Parkinsonian drugs.
Bang JI; Jung IS; Song YS; Park HS; Moon BS; Lee BC; Kim SE
Nucl Med Biol; 2016 Feb; 43(2):158-64. PubMed ID: 26872440
[TBL] [Abstract][Full Text] [Related]
4. Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients.
Sonni I; Fazio P; Schain M; Halldin C; Svenningsson P; Farde L; Varrone A
J Nucl Med; 2016 Oct; 57(10):1529-1534. PubMed ID: 27230923
[TBL] [Abstract][Full Text] [Related]
5. Quantification and discriminative power of
Delva A; Van Weehaeghe D; van Aalst J; Ceccarini J; Koole M; Baete K; Nuyts J; Vandenberghe W; Van Laere K
Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1913-1926. PubMed ID: 31776633
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal DAT changes measured with [
Kerstens VS; Fazio P; Sundgren M; Brumberg J; Halldin C; Svenningsson P; Varrone A
Neuroimage Clin; 2023; 37():103347. PubMed ID: 36822016
[TBL] [Abstract][Full Text] [Related]
7. Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease.
Pagano G; Niccolini F; Wilson H; Yousaf T; Khan NL; Martino D; Plisson C; Gunn RN; Rabiner EA; Piccini P; Foltynie T; Politis M
Mov Disord; 2019 Oct; 34(10):1505-1515. PubMed ID: 31158314
[TBL] [Abstract][Full Text] [Related]
8. Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa.
Poyot T; Condé F; Grégoire MC; Frouin V; Coulon C; Fuseau C; Hinnen F; Dollé F; Hantraye P; Bottlaender M
J Cereb Blood Flow Metab; 2001 Jul; 21(7):782-92. PubMed ID: 11435790
[TBL] [Abstract][Full Text] [Related]
9. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.
Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J
J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Positron Emission Tomography Imaging of Presynaptic Terminals in Early Parkinson's Disease.
Delva A; Van Laere K; Vandenberghe W
Mov Disord; 2022 Sep; 37(9):1883-1892. PubMed ID: 35819412
[TBL] [Abstract][Full Text] [Related]
11. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
[TBL] [Abstract][Full Text] [Related]
12. Dynamic properties in functional connectivity changes and striatal dopamine deficiency in Parkinson's disease.
Asendorf AL; Theis H; Tittgemeyer M; Timmermann L; Fink GR; Drzezga A; Eggers C; Ruppert-Junck MC; Pedrosa DJ; Hoenig MC; van Eimeren T
Hum Brain Mapp; 2024 Jul; 45(10):e26776. PubMed ID: 38958131
[TBL] [Abstract][Full Text] [Related]
13. Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F-dopa PET study.
Pavese N; Rivero-Bosch M; Lewis SJ; Whone AL; Brooks DJ
Neuroimage; 2011 Jun; 56(3):1463-8. PubMed ID: 21396455
[TBL] [Abstract][Full Text] [Related]
14. Progressive changes of pre- and post-synaptic dopaminergic biomarkers in conscious MPTP-treated cynomolgus monkeys measured by positron emission tomography.
Nagai Y; Obayashi S; Ando K; Inaji M; Maeda J; Okauchi T; Ito H; Suhara T
Synapse; 2007 Oct; 61(10):809-19. PubMed ID: 17598150
[TBL] [Abstract][Full Text] [Related]
15. [
Stark AJ; Smith CT; Petersen KJ; Trujillo P; van Wouwe NC; Donahue MJ; Kessler RM; Deutch AY; Zald DH; Claassen DO
Neuroimage Clin; 2018; 18():433-442. PubMed ID: 29541577
[TBL] [Abstract][Full Text] [Related]
16. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.
Brooks DJ; Salmon EP; Mathias CJ; Quinn N; Leenders KL; Bannister R; Marsden CD; Frackowiak RS
Brain; 1990 Oct; 113 ( Pt 5)():1539-52. PubMed ID: 2123119
[TBL] [Abstract][Full Text] [Related]
17. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study.
Brück A; Aalto S; Nurmi E; Vahlberg T; Bergman J; Rinne JO
Mov Disord; 2006 Jul; 21(7):958-63. PubMed ID: 16550545
[TBL] [Abstract][Full Text] [Related]
18. Simplified quantification of [
Brumberg J; Kerstens V; Cselényi Z; Svenningsson P; Sundgren M; Fazio P; Varrone A
J Cereb Blood Flow Metab; 2021 Jun; 41(6):1291-1300. PubMed ID: 32955955
[TBL] [Abstract][Full Text] [Related]
19. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Morrish PK; Rakshi JS; Bailey DL; Sawle GV; Brooks DJ
J Neurol Neurosurg Psychiatry; 1998 Mar; 64(3):314-9. PubMed ID: 9527140
[TBL] [Abstract][Full Text] [Related]
20. Parkinson's disease laterality: a
Roussakis AA; Zeng Z; Lao-Kaim NP; Martin-Bastida A; Piccini P;
J Neurol; 2021 Feb; 268(2):582-589. PubMed ID: 32880071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
